The FDA’s Pharmacy Compounding Advisory Committee will be considering the addition of four new ingredients for use for inclusion on the bulk list for 503A compounders to utilize in the compounding of prescription drug products. The four ingredients up for consideration are:
- Ammonium tetrathiomolybdate;
- Enclomiphene citrate;
- Ferric subsulfate; and
The Notice for the Advisory Committee meeting also describes the uses for which these ingredients are being considered.
The Agency is also considering adding Lorcaserin Hydrochloride (in any form) to the Withdrawn or Removed List.
The meeting will be held virtually tomorrow, June 8th. Additional information regarding access to the meeting can be found here.